Cargando…
Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients
Anti-programmed death-1 (PD-1) therapy has been extensively used to treat cancer. Recently, the combination of immunotherapy and anti-angiogenic therapy has emerged as a novel treatment approach. Therefore, we designed a study to evaluate the real-world benefit of the combination of anti-PD-1 and an...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302578/ https://www.ncbi.nlm.nih.gov/pubmed/32541476 http://dx.doi.org/10.1097/MD.0000000000020545 |
_version_ | 1783547876025040896 |
---|---|
author | Qiu, Lupeng Zhao, Xiao Shi, Weiwei Sun, Shengjie Zhang, Guoqing Sun, Qiong Meng, Jing Xiong, Qi Qin, Boyu Jiao, Shunchang |
author_facet | Qiu, Lupeng Zhao, Xiao Shi, Weiwei Sun, Shengjie Zhang, Guoqing Sun, Qiong Meng, Jing Xiong, Qi Qin, Boyu Jiao, Shunchang |
author_sort | Qiu, Lupeng |
collection | PubMed |
description | Anti-programmed death-1 (PD-1) therapy has been extensively used to treat cancer. Recently, the combination of immunotherapy and anti-angiogenic therapy has emerged as a novel treatment approach. Therefore, we designed a study to evaluate the real-world benefit of the combination of anti-PD-1 and anti-angiogenesis therapy in patients with non-small cell lung cancer (NSCLC). We obtained the medical records of patients at the Chinese People's Liberation Army General Hospital who received either nivolumab or pembrolizumab combined with anti-angiogenesis therapy from January 2015 to December 2018. The overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated for all patients. Sixty-nine patients with NSCLC were included in our study. The ORR was 31.9% (95% CI: 20.6–43.2%) and the median PFS was 8.37 months (95% CI: 6.5–10.0 months). The subgroup analysis statistically revealed a significant difference in ORR for patients receiving first-line treatment vs other lines, and the values were 58.8% (95% CI: 32.7–84.9%) compared with 23.1% (95% CI: 11.2–34.9%). We also observed a significant improvement in PFS, with a median value of 10.5 months (95% CI: 7.4–13.1 months) for patients without EGFR mutations and 5.4 months (95% CI: 4.0–6.3 months) for patients with EGFR mutations. The real-world ORR, PFS, and OS were comparable to previous clinical trials, despite the patients’ different baseline characteristics. Importantly, compared with patients having identified EGFR mutations, patients without EGFR mutations had a better PFS. Furthermore, these data support the use of anti-PD-1 combined with anti-angiogenesis therapy as a novel treatment approach for patients with NSCLC. |
format | Online Article Text |
id | pubmed-7302578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-73025782020-06-29 Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients Qiu, Lupeng Zhao, Xiao Shi, Weiwei Sun, Shengjie Zhang, Guoqing Sun, Qiong Meng, Jing Xiong, Qi Qin, Boyu Jiao, Shunchang Medicine (Baltimore) 5700 Anti-programmed death-1 (PD-1) therapy has been extensively used to treat cancer. Recently, the combination of immunotherapy and anti-angiogenic therapy has emerged as a novel treatment approach. Therefore, we designed a study to evaluate the real-world benefit of the combination of anti-PD-1 and anti-angiogenesis therapy in patients with non-small cell lung cancer (NSCLC). We obtained the medical records of patients at the Chinese People's Liberation Army General Hospital who received either nivolumab or pembrolizumab combined with anti-angiogenesis therapy from January 2015 to December 2018. The overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated for all patients. Sixty-nine patients with NSCLC were included in our study. The ORR was 31.9% (95% CI: 20.6–43.2%) and the median PFS was 8.37 months (95% CI: 6.5–10.0 months). The subgroup analysis statistically revealed a significant difference in ORR for patients receiving first-line treatment vs other lines, and the values were 58.8% (95% CI: 32.7–84.9%) compared with 23.1% (95% CI: 11.2–34.9%). We also observed a significant improvement in PFS, with a median value of 10.5 months (95% CI: 7.4–13.1 months) for patients without EGFR mutations and 5.4 months (95% CI: 4.0–6.3 months) for patients with EGFR mutations. The real-world ORR, PFS, and OS were comparable to previous clinical trials, despite the patients’ different baseline characteristics. Importantly, compared with patients having identified EGFR mutations, patients without EGFR mutations had a better PFS. Furthermore, these data support the use of anti-PD-1 combined with anti-angiogenesis therapy as a novel treatment approach for patients with NSCLC. Wolters Kluwer Health 2020-06-12 /pmc/articles/PMC7302578/ /pubmed/32541476 http://dx.doi.org/10.1097/MD.0000000000020545 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 5700 Qiu, Lupeng Zhao, Xiao Shi, Weiwei Sun, Shengjie Zhang, Guoqing Sun, Qiong Meng, Jing Xiong, Qi Qin, Boyu Jiao, Shunchang Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients |
title | Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients |
title_full | Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients |
title_fullStr | Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients |
title_full_unstemmed | Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients |
title_short | Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients |
title_sort | real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302578/ https://www.ncbi.nlm.nih.gov/pubmed/32541476 http://dx.doi.org/10.1097/MD.0000000000020545 |
work_keys_str_mv | AT qiulupeng realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT zhaoxiao realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT shiweiwei realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT sunshengjie realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT zhangguoqing realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT sunqiong realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT mengjing realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT xiongqi realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT qinboyu realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients AT jiaoshunchang realworldtreatmentefficacyofantiprogrammeddeath1combinedwithantiangiogenesistherapyinnonsmallcelllungcancerpatients |